CN113730560A - Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof - Google Patents

Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof Download PDF

Info

Publication number
CN113730560A
CN113730560A CN202110899673.5A CN202110899673A CN113730560A CN 113730560 A CN113730560 A CN 113730560A CN 202110899673 A CN202110899673 A CN 202110899673A CN 113730560 A CN113730560 A CN 113730560A
Authority
CN
China
Prior art keywords
eye
eyes
soothing
extract
brightening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110899673.5A
Other languages
Chinese (zh)
Inventor
付永旭
邱发洋
黄丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Zhongke Yimei Biotechnology Co ltd
Original Assignee
Guangzhou Zhongke Yimei Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Zhongke Yimei Biotechnology Co ltd filed Critical Guangzhou Zhongke Yimei Biotechnology Co ltd
Priority to CN202110899673.5A priority Critical patent/CN113730560A/en
Publication of CN113730560A publication Critical patent/CN113730560A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention belongs to the field of daily chemicals. A spray eye washing liquid for brightening and soothing bright eyes comprises the following components: allantoin, butanediol, sodium hyaluronate, compound biological enzyme, lutein, taurine, plant extract, lactic acid, 1, 2-hexanediol, caprylyl glycine and the balance of water. The eye lotion can efficiently inject energy into eyes by utilizing a vesicle running theory and a dehydrogenation oxygen supply technology, improve the metabolic capacity of the eyes, remove black eye circles, eliminate edema, tighten the eye circumference, desalt fine lines, quickly decompose and clean eye rubbish, brighten eyes immediately, clear vision, dredge eye microcirculation, reduce intraocular pressure, relieve eye fatigue and dryness, and effectively prevent and relieve various common eye diseases. Convenient use, green safety, quick response and good effect.

Description

Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof
Technical Field
The invention belongs to the field of daily chemicals, and particularly relates to a spraying eye washing liquid for brightening and soothing eyes and a preparation method thereof.
Background
With the popularization of electronic products, eye problems caused by overuse of eyes and eye fatigue are increasingly serious, but the existing eye care products cannot quickly and efficiently solve the eye problems, eye protection products such as eye drops and eye patches are inconvenient to use, slow in effectiveness and poor in curative effect. Therefore, an eye care product which is green, safe, convenient to use, quick in effect and good in effect on common eye problems is needed.
Disclosure of Invention
The invention aims to solve the technical problem of providing a spray eye washing liquid for brightening and soothing eyes, which can efficiently inject energy into eyes by utilizing a vesicle running theory and a dehydrogenation oxygen supply technology, improve the metabolic capability of the eyes, remove dark circles, eliminate edema, tighten the periphery of the eyes, fade fine lines, quickly decompose and clean rubbish in the eyes, brighten eyes immediately, clear vision, dredge microcirculation of the eyes, reduce intraocular pressure, relieve fatigue and dryness of the eyes and effectively prevent and relieve various common eye diseases. Convenient use, green safety, quick response and good effect.
The technical scheme of the invention is as follows:
a spray eye washing liquid for brightening and soothing eyes comprises the following components in percentage by mass: allantoin 0.6-0.8%, butanediol 0.5-2%, sodium hyaluronate 0.001-0.05%, compound biological enzyme 0.01-0.2%, xanthophyll 0.01-0.02%, taurine 0.01-0.4%, plant extract 0.01-1.5%, lactic acid 0.01-0.6%, 1, 2-hexanediol 0.1-0.6%, caprylyl glycine 0.1-0.6%, and the balance of water.
A.Biological compound enzyme
The biological compound enzyme is formed by combining a plurality of enzymes, and can realize the catalytic effects of the enzymes: inhibiting bacteria, relieving inflammation, scavenging free radicals, resisting aging, and repairing skin and mucosa barrier. By contacting epithelial cells with it, the metabolite H of the cells themselves is utilized2O, dehydrogenate and gather oxygen, can make the oxygen content of cell promote rapidly to can activate the cell of deep sleep and sub-dormancy state, promote cell renewal and tissue metabolism, promote the cell to carry out the vesicle and transport, after the microcirculation of skin is dredged, the skin clears away the passageway of free radical and transportation nourishment more unobstructed, solves the initiative absorption problem of skin fundamentally, can promote epithelial cell to obtain the restoration hyperplasia after the microcirculation of skin is dredged, solves a series of skin problems because of cell water deficiency oxygen deficiency causes.
B.Allantoin
Allantoin has the functions of shading, sterilizing, preventing corrosion, relieving pain, resisting oxidation, protecting tissue, keeping skin moisture, moistening and softening, promoting cell growth, accelerating wound healing, softening keratin and other physiological functions, accelerating cell proliferation and differentiation, rapidly forming epidermal layer, and realizing the effects of repairing skin around eyes, inducing regeneration, and caring skin. However, allantoin is poor in water solubility, and when added to a general skin care product in an amount of only 0.3%, it precipitates and the aqueous product exhibits needle-like coagulates, crystals, etc. The applicant has proved, through a large number of experiments: the low concentration of allantoin is far from sufficient for skin care and repair, thus limiting the use of allantoin in skin care and pharmaceutical products. Experiments prove that the addition amount of the allantoin in the skin care product reaches 0.6% or more, and the excellent new skin care effect can be shown. The addition of the allantoin is 0.6-0.8%, and a structure similar substance which is easy to dissolve in water is grafted on the molecule, so that the water solubility of the allantoin is greatly improved, the outer cutin can be removed, hair follicles are dredged, microcirculation is promoted, the transdermal absorption efficiency of active ingredients is improved, the skin color is improved and uniform, and black eye circles are lightened; promoting cell tissue growth, accelerating wound healing, removing and resisting wrinkles, and compacting the eye circumference; the eye cream has excellent anti-allergic effect, enhances the immunity of skin, helps the eyes resist environmental stimulation, relieves eye fatigue and prevents eye diseases; can moisturize and keep moisture for a long time, keep eye skin moist and avoid dry eyes.
C.Xanthophyll
Lutein is the most important nutrient component of retina as a photosynthetic pigment, and also is the most main necessary component forming a macular region of the retina, ultraviolet rays and blue light in sunlight enter eyes to generate a large amount of free radicals, the ultraviolet rays can be usually filtered by cornea and crystalline lens of the eyes, the blue light can penetrate eyeballs to directly reach the retina and macula lutea, the lutein in the macular region can filter the blue light to avoid the blue light from damaging the eyes, but the outer fat layer of the macular region is easily oxidized and damaged by the sunlight, so that the macular region is easily degraded, and eye diseases such as cataract and the like are caused. The lutein is used as antioxidant, has good antioxidant effect, and can play a role in photoprotection and nutrition of retinal photoreceptor cells in photodamage to prevent apoptosis, thereby protecting eyesight, delaying aging of eyes and preventing and treating eye diseases. Effectively promote the regeneration of rhodopsin in retinal cells, prevent severe myopia and retinal detachment, improve eyesight, protect eyesight, relieve asthenopia symptoms such as blurred vision, dry eye, eye swelling, ophthalmalgia, photophobia and the like, improve the pigment density of yellow spots, protect yellow spots, promote the development of yellow spots, prevent macular degeneration and retinitis pigmentosa, reduce the generation of drusen and prevent the occurrence of senile macular degeneration.
D.Taurine
Taurine, also called beta-aminoethanesulfonic acid, is a sulfur-containing non-protein amino acid, is the most abundant amino acid in retina, vitreous body, crystalline lens, cornea, iris and ciliary body, can protect retina, has the functions of regulating the osmotic pressure of crystal and resisting oxidation, and can inhibit the oxidation of protein in the crystal, thereby avoiding the occurrence of cataract. Taurine has antibacterial, anti-inflammatory, and tranquilizing effects, and can be used for effectively relieving asthenopia, maintaining visual function, and protecting vision.
Further, the compound biological enzyme comprises at least one of the following enzymes, namely, celloprotease, lysozyme, superoxide dismutase, glutathione peroxidase and catalase.
Further, the composite biological enzyme comprises the following components of fibrous protease, lysozyme, superoxide dismutase, glutathione peroxidase and catalase in a mass ratio of 1:1-3:1-3: 1-3.
Further, the plant extract includes at least one of dandelion extract, centella asiatica extract, and aloe vera extract.
The dandelion extract has the effects of inhibiting bacteria, diminishing inflammation, promoting cell growth, scavenging free radicals, resisting oxidation, delaying aging, tightening eye periphery, removing wrinkles and wrinkles, protecting retina, improving eyesight and relieving common eye diseases. The centella asiatica extract can resist bacteria and diminish inflammation, clear free radicals, resist oxidation, stimulate fibroblast proliferation and differentiation, remarkably improve the content of collagen and cell layer fibronectin, repair the barrier function of skin, improve the water content of skin, recover the elasticity of eye skin and delay skin aging. The aloe extract can promote fibrin growth and collagen synthesis, inhibit elastin, scavenge free radicals, resist bacteria, relieve inflammation, supplement water, keep moisture, recover eye skin elasticity, and relieve eye dryness.
Further, the plant extract is 0.02-1% of dandelion extract, 0.01-0.6% of centella asiatica extract and 0.01-0.6% of aloe extract.
Further, the preservative is 0.001-0.01%.
Further, the preservative is methyl ester.
The preparation method of the spray eye washing liquid for brightening and soothing eyes comprises the following steps: mixing water, butanediol, allantoin, sodium hyaluronate, and compound biological enzyme, heating to 85-95 deg.C, and stirring for 20-30 min; cooling to 39-45 deg.C, adding mixture of 1, 2-hexanediol and caprylyl glycine, and stirring for 10-20 min; cooling to below 37 deg.C, adding lutein, taurine, plant extract and lactic acid, and stirring for 10-20 min.
The invention has the following beneficial effects:
according to the invention, through compounding of various plant extracts and active ingredients, eye skin cells can be deeply nourished, collagen and elastic fibers can be efficiently supplemented, the eye skin can be full of elasticity, the skin around the eyes can be tightly firmed, and wrinkles can be removed; the eye-care product can efficiently decompose eye garbage, dredge eye cell microcirculation, accelerate metabolism, relieve eye fatigue and dryness, brighten eyes, clear vision, prevent myopia, protect eyesight, replenish water, moisten, repair, diminish inflammation, relieve itching, heal wounds, decompose free radicals, promote metabolism, and effectively prevent and relieve eye diseases such as eye fatigue, myopia amblyopia, dryness and itching, eye soreness, red blood streak, keratitis, muscae volitantes, presbyopia, and epiphora induced by wind.
Detailed Description
The present invention will be described in detail with reference to examples, which are only preferred embodiments of the present invention and are not intended to limit the present invention.
Examples
The following table is a formula table (unit:%) of 3 examples of the bright and soothing spray eyewash of the present invention:
Figure BDA0003199180230000041
Figure BDA0003199180230000051
the preparation method of the spray eye washing liquid for brightening and soothing eyes comprises the following steps: mixing water, butanediol, allantoin, sodium hyaluronate, and compound biological enzyme, heating to 85 deg.C, and stirring for 20 min; cooling to 39 deg.C, adding mixture of 1, 2-hexanediol and caprylyl glycine, and stirring for 10 min; cooling to below 37 deg.C, adding lutein, taurine, plant extract and lactic acid, and stirring for 10 min.
Comparative example
The following table shows the formulation of 3 comparative examples of bright and soothing eye spray eyewash according to the present invention (unit:%), prepared by mixing and stirring as conventional in the art:
Figure BDA0003199180230000052
Figure BDA0003199180230000061
the performance of 3 examples and 3 comparative examples of bright and soothing spray eyewash according to the invention was tested:
first, relieve red blood streak and corneal ectasia test
After a phenol aqueous solution with the concentration of 3M is sterilized, 10 mu L of the phenol aqueous solution is taken and applied to centers of two eyes of 2-month-old rats with healthy eyes and no red blood streak, the application period is one porridge, the application is performed once a day, 30 rats with blood vessels and corneal dilatation phenomena appearing in two eyes are selected and divided into three groups A, B and C, 10 rats in each group are selected, the left eye and the right eye of the group A are respectively applied with the example 1 and the comparative example 1, the left eye and the right eye of the group B are respectively applied with the example 2 and the comparative example 2, the left eye and the right eye of the group C are respectively applied with the example 3 and the comparative example 3 with the dosage of 1ml, one drop of the sample is applied for absorption and then applied, the application time duration of each time is 10-30min, the test period is 7 days, the number of the rats with the healed, effective and ineffective eye red blood streak and keratoconus after 7 days is observed and counted, and the test results are shown in the following table:
Figure BDA0003199180230000062
therefore, the invention can effectively relieve the phenomena of red blood streak and corneal dilatation of eyes, and has quick response and short treatment course.
Second, testing for treating cataract
Selecting 60 cataract patients over 60 years old and close to the disease degree, dividing the cataract patients into 6 groups, applying 5ml samples to wash eyes in the morning and at night, wherein the contact time of eye washing liquid and the diseased part is more than or equal to 60s, the test period is 20 days, observing the reduction of pearl opacities and the recovery condition of vision of the patients after 20 days, counting the number of recovery, effectiveness and ineffectiveness, and the test result is shown in the following table:
Figure BDA0003199180230000063
Figure BDA0003199180230000071
therefore, the traditional Chinese medicine composition has a good treatment effect on cataract, and is quick in effect taking and short in treatment course.
Third, test for improving skin around eyes
1. And (3) testing items: skin melanin content, moisture content, skin elasticity.
2. Testing an instrument: CKMPA580 skin tester, Mexameter skin melanin test probe, Corneometer moisture test probe, Cutometer skin elasticity test probe.
3. A subject: and (4) screening qualified volunteers with dark eye circles, puffy pouches and no eye diseases on eyes, and selecting the eye periphery as a test part. Examples 1-3, comparative examples 1-3 20 subjects each per group.
4. And (3) testing period: the test period was 15 days, and each index was measured using the instrument 1 day before and 15 days after using the sample. In the post-use test, the volunteer could not apply the sample on the day of the test, and the sample was used after the test was completed.
5. Sample use: the 1 week prior to testing was the elution period during which subjects used basal moisturizing water and moisturizing milk without any actives. Other whitening products cannot be used during the test. The subjects used the samples for 15 consecutive days, and the samples were coated around the eyes every day in the morning and at night after washing the face before sleeping in an amount of about 0.5 ml. The melanin content was tested on the face as a self control.
6. The testing process comprises the following steps: data acquisition before use: before testing, sit in a constant temperature and humidity room with the temperature of 24 +/-1 ℃ and the humidity of 55 +/-5% RH for 20 minutes. Pre-use data were collected at the test site using a Mexameter skin melanin test probe, a Corneometer moisture test probe, and a Cutometer skin elasticity test probe. And (4) carrying out cycle test on each test point of each test part for 4 times, and taking an average value as the data before use of the corresponding part.
7. Data collection on day 15 after use, the procedure was the same as before use.
8. The test results are given in the following table:
(1)：
Figure BDA0003199180230000072
Figure BDA0003199180230000081
therefore, the eye lotion can obviously reduce the content of skin melanin, increase the content of skin moisture, improve the skin elasticity, effectively remove dark eye circles and tighten the skin around the eyes.
The eye lotion can efficiently inject energy into eyes by utilizing a vesicle running theory and a dehydrogenation oxygen supply technology, improve the metabolic capacity of the eyes, remove black eye circles, eliminate edema, tighten the eye circumference, desalt fine lines, quickly decompose and clean eye rubbish, brighten eyes immediately, clear vision, dredge eye microcirculation, reduce intraocular pressure, relieve eye fatigue and dryness, and effectively prevent and relieve various common eye diseases. Convenient use, green safety, quick response and good effect.

Claims (8)

1. The spray eye washing liquid for brightening and soothing the bright eyes is characterized by comprising the following components in percentage by mass: allantoin 0.6-0.8%, butanediol 0.5-2%, sodium hyaluronate 0.001-0.05%, compound biological enzyme 0.01-0.2%, xanthophyll 0.01-0.02%, taurine 0.01-0.4%, plant extract 0.01-1.5%, lactic acid 0.01-0.6%, 1, 2-hexanediol 0.1-0.6%, caprylyl glycine 0.1-0.6%, and the balance of water.
2. The brightly and soothe spray eye wash of claim 1, wherein the complex biological enzyme comprises at least one of a cellulase, lysozyme, superoxide dismutase, glutathione peroxidase, catalase.
3. The brightly and soothing spray eye wash according to claim 1, wherein the complex bio-enzyme is a mixture of a protease, lysozyme, superoxide dismutase, glutathione peroxidase and catalase in a mass ratio of 1:1-3:1-3:1-3: 1-3.
4. The brightly and soothe spray eye wash of claim 1, wherein the plant extract comprises at least one of a dandelion extract, a centella asiatica extract, and an aloe vera extract.
5. The brightly and soothe spray eye wash of claim 1, wherein the plant extracts are dandelion extract 0.02-1%, centella asiatica extract 0.01-0.6% and aloe vera extract 0.01-0.6%.
6. The spray eye wash according to claim 1, further comprising a preservative 0.001-0.01%.
7. The brightly and soothing spray eye wash according to claim 6, wherein the preservative is methyl ester.
8. A method of preparing a spray eye wash for brightening and soothing the eyes according to any one of claims 1 to 7, comprising the steps of: mixing water, butanediol, allantoin, sodium hyaluronate, and compound biological enzyme, heating to 85-95 deg.C, and stirring for 20-30 min; cooling to 39-45 deg.C, adding mixture of 1, 2-hexanediol and caprylyl glycine, and stirring for 10-20 min; cooling to below 37 deg.C, adding lutein, taurine, plant extract and lactic acid, and stirring for 10-20 min.
CN202110899673.5A 2021-08-06 2021-08-06 Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof Pending CN113730560A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110899673.5A CN113730560A (en) 2021-08-06 2021-08-06 Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110899673.5A CN113730560A (en) 2021-08-06 2021-08-06 Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113730560A true CN113730560A (en) 2021-12-03

Family

ID=78730293

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110899673.5A Pending CN113730560A (en) 2021-08-06 2021-08-06 Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113730560A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116726151A (en) * 2023-03-13 2023-09-12 河北纳科生物科技有限公司 Daily throwing eye drops for cornea damage repair and preparation method thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
CN101716214A (en) * 2009-12-23 2010-06-02 四川大学 Medical composition containing dandelion extract as well as novel application and preparation method thereof
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
CN102178925A (en) * 2011-04-25 2011-09-14 崔晓廷 Novel eyesight protective agent lutein ophthalmic preparation
WO2017130130A1 (en) * 2016-01-28 2017-08-03 Roberto Pinelli Nutritional supplement for maintaining the state of health of the eye
RU2660366C1 (en) * 2017-03-31 2018-07-05 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Agent for prevention and treatment of ocular diseases, such as retinal diseases, glaucoma and cataract
CN110123695A (en) * 2019-06-03 2019-08-16 惠州学院 A kind of cellular energy remediation composition
CN110787082A (en) * 2019-09-29 2020-02-14 广州达达眼健康管理有限公司 Eye cell repair composition and eye care product containing same
CN112999124A (en) * 2021-03-04 2021-06-22 同方药业集团有限公司 Eye-protecting spray and preparation method thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
CN101716214A (en) * 2009-12-23 2010-06-02 四川大学 Medical composition containing dandelion extract as well as novel application and preparation method thereof
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
CN102178925A (en) * 2011-04-25 2011-09-14 崔晓廷 Novel eyesight protective agent lutein ophthalmic preparation
WO2017130130A1 (en) * 2016-01-28 2017-08-03 Roberto Pinelli Nutritional supplement for maintaining the state of health of the eye
RU2660366C1 (en) * 2017-03-31 2018-07-05 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Agent for prevention and treatment of ocular diseases, such as retinal diseases, glaucoma and cataract
CN110123695A (en) * 2019-06-03 2019-08-16 惠州学院 A kind of cellular energy remediation composition
CN110787082A (en) * 2019-09-29 2020-02-14 广州达达眼健康管理有限公司 Eye cell repair composition and eye care product containing same
CN112999124A (en) * 2021-03-04 2021-06-22 同方药业集团有限公司 Eye-protecting spray and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李佳圆: "常见慢性非传染性疾病的防治 第2版", 30 April 2021, 四川大学出版社, pages: 168 *
高兴华;刘小杰;欧凯;: "视疲劳与营养干预", 饮料工业, no. 06, 28 June 2010 (2010-06-28) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116726151A (en) * 2023-03-13 2023-09-12 河北纳科生物科技有限公司 Daily throwing eye drops for cornea damage repair and preparation method thereof
CN116726151B (en) * 2023-03-13 2024-04-09 河北纳科生物科技有限公司 Daily throwing eye drops for cornea damage repair and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102935055B (en) Hydrolat moisturizing facial mask
CN113304310A (en) Medical wet dressing with repairing function and preparation method thereof
KR20200139970A (en) Shampoo for preventing loss of hair andpromoting growth of hair and method for manufacturing the same
CN100453086C (en) Gel for removing ocular by ice pearl and its preparation
CN111514055A (en) Cosmetic polypeptide composition granules with anti-inflammatory repair effect
CN113730560A (en) Spraying eye washing liquid for brightening and soothing bright eyes and preparation method thereof
CN113952277A (en) Microcrystalline peptide anti-wrinkle face cream and preparation method thereof
CN111067820A (en) Plant repair essence milk and preparation method thereof
CN111658592A (en) Eye essence and preparation method thereof
CN107519118A (en) A kind of snake gall eye mask and preparation method thereof
CN110859758A (en) Whitening anti-aging repair type medical cold compress patch and preparation method thereof
CN113069373A (en) Dry eye cream, preparation method and application
CN113230154B (en) Composition with anti-allergy, relieving and anti-inflammation effects and preparation method and application thereof
CN113925828A (en) Borneol eye lotion
CN109453104B (en) Spot-fading skin-refreshing essence and preparation process thereof
CN113332175A (en) Medical wet repairing plaster
CN113274337A (en) Medical skin repairing and nursing film and preparation method thereof
CN105902686A (en) In-situ gel eyewash containing nano-carbon crystals and preparation method thereof
CN108078906B (en) Tea oil hair mask for hair waving and dyeing and preparation method and application thereof
CN114099551B (en) Asthenopia-relieving and eye-moistening composition
CN115364028B (en) Biological peptide activation repairing mask liquid and preparation method thereof
KR20090003828A (en) Hair tonic containing composite for growig hair and preventing fall-out of hair
CN113181087B (en) Fine grain removing composition, application thereof and eye care patch
CN116617115B (en) Mild and tear-free active ingredient composition and application thereof in washing and caring products
CN114617792B (en) Anti-aging composition, preparation method and application thereof, and anti-aging skin care product

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination